Liquid Biopsy

Investigators in this area explore the potential of liquid biopsies for diagnosing and monitoring diseases, particularly cancer. This research focuses on identifying and analyzing biomarkers, such as circulating tumor DNA (ctDNA), RNA, proteins, and extracellular vesicles, found in bodily fluids like blood, urine, and saliva. Techniques employed include advanced molecular biology methods, mass spectrometry, and bioinformatics to detect subtle molecular changes associated with disease development and progression, aiming to enable earlier detection, personalized treatment strategies, and non-invasive disease monitoring.

The development of liquid biopsy technologies holds significant promise for Arkansas's public health initiatives. Given the state's cancer burden, this research can contribute to improved early detection rates and more effective patient management, potentially reducing healthcare costs and improving outcomes. Furthermore, advancements in this field can foster growth in the state's biotechnology and healthcare sectors, creating opportunities for innovation and economic development.

This research is inherently interdisciplinary, drawing upon expertise in molecular biology, genomics, diagnostics, mass spectrometry, and bioinformatics. Collaboration extends across multiple institutions within Arkansas, integrating diverse skill sets to advance the field and its applications.